PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
48.96%
Some net income increase while AVXL is negative at -43.19%. John Neff would see a short-term edge over the struggling competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1.88%
SBC growth of 1.88% while AVXL is zero at 0.00%. Bruce Berkowitz would see some additional share issuance that must be justified by expansions or retention needs.
-128.88%
Negative yoy working capital usage while AVXL is 725.80%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-244.33%
Negative yoy AP while AVXL is 0.00%. Joel Greenblatt would see quicker payments or less reliance on trade credit than competitor, unless expansions are hindered.
1043.06%
Growth well above AVXL's 725.80%. Michael Burry would see a potential hidden liquidity or overhead issue overshadowing competitor's approach.
-114.48%
Both negative yoy, with AVXL at -2.84%. Martin Whitman would suspect an overall environment of intangible cleanup or shifting revaluations for the niche.
-59.54%
Negative yoy CFO while AVXL is 75.10%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
2.03%
Debt repayment growth of 2.03% while AVXL is zero at 0.00%. Bruce Berkowitz sees a mild advantage that can reduce interest costs unless expansions demand capital here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.